

Sales of major prescription pharmaceuticals

(Millions of yen)

Brand name Generic name/formulation	Therapeutic category	Three months ended December 31, 2005 Actual	Nine months ended December 31, 2005 Actual	Year ended March 31, 2006 Actual	Three months ended December 31, 2006 Actual	Nine months ended December 31, 2006 Actual	Year ending March 31, 2007 Forecasts
Prescription pharmaceuticals		25,022 (8.6)	70,583 (10.9)	90,251 (7.1)	24,219 (3.2)	71,271 (1.0)	91,790 (1.7)
Cravit levofloxacin/ophthalmic solution	Bacterial conjunctivitis	3,686 (8.2)	10,769 (3.3)	13,227 (3.1)	3,453 (6.3)	10,680 (0.8)	12,930 (2.2)
Tarivid ofloxacin/ophthalmic solution	Bacterial conjunctivitis	1,058 (4.8)	3,384 (6.8)	4,100 (7.4)	774 (26.8)	2,811 (16.9)	3,460 (15.6)
Timoptol timolol maleate/ophthalmic solution	Glaucoma	1,211 (3.1)	3,401 (3.8)	4,210 (4.6)	1,069 (11.7)	3,044 (10.5)	3,790 (10.0)
Timoptol XE timolol maleate/ long-acting ophthalmic solution	Glaucoma	887 (8.9)	2,433 (9.4)	3,072 (8.3)	935 (5.4)	2,550 (4.8)	3,210 (4.5)
Pivalephrine dipivefrine hydrochloride	Glaucoma	94 (13.1)	268 (16.2)	324 (17.6)	80 (15.2)	229 (14.4)	270 (16.7)
Detantol bunazosin hydrochloride	Glaucoma	651 (5.9)	1,784 (4.1)	2,226 (3.3)	647 (0.7)	1,805 (1.2)	2,330 (4.7)
Rescula unoprostone isopropyl	Glaucoma	1,486 (7.3)	4,107 (156.3)	5,152 (94.7)	1,501 (1.0)	4,092 (0.4)	5,210 (1.2)
Livostin levocabastine hydrochloride/ ophthalmic solution	Allergy	816 (5.2)	2,294 (4.3)	3,984 (19.0)	798 (2.2)	2,455 (7.0)	4,470 (12.2)
Alegysal pemirolast potassium/ophthalmic solution	Allergy	182 (7.2)	515 (10.2)	749 (21.5)	159 (12.7)	519 (0.6)	740 (1.2)
Hyalein sodium hyaluronate/ophthalmic solution	Corneal disease	4,862 (16.0)	13,250 (13.3)	16,879 (12.6)	5,060 (4.1)	14,083 (6.3)	17,980 (6.5)
Flumetholon fluorometholone/ophthalmic solution	Inflammation	1,300 (9.4)	3,746 (0.2)	4,879 (8.9)	1,206 (7.2)	3,672 (2.0)	4,830 (1.0)
Kary Uni pirenoxine/ophthalmic solution	Early-stage senile cataract	911 (1.8)	2,614 (1.7)	3,341 (3.8)	983 (7.9)	2,743 (4.9)	3,460 (3.6)
Opegan Hi sodium hyaluronate/ adjuvant for ophthalmic operations	Adjuvant for ophthalmic operations	797 (15.2)	2,200 (19.0)	2,746 (15.7)	823 (3.3)	2,244 (2.0)	2,890 (5.2)
BSS PLUS oxiglutatione/ophthalmic perfusate and lotion	Perfusate / lotion	380 (7.0)	1,057 (4.2)	1,316 (3.3)	355 (6.5)	1,014 (4.0)	1,290 (2.0)
Rimatil bucillamine/tablet	Rheumatoid arthritis	1,478 (7.1)	4,055 (4.3)	5,033 (3.1)	1,333 (9.8)	3,942 (2.8)	4,970 (1.3)
Azulfidine EN salazosulfapyridine/enteric coated tablet	Rheumatoid arthritis	1,080 (9.8)	2,963 (10.9)	3,717 (10.1)	1,117 (3.4)	3,075 (3.7)	3,860 (3.8)
Prescription ophthalmic pharmaceuticals for U.S.A. (Quixin, Betimol and Alamast)		233 (67.6)	617 (88.2)	1,149 (47.0)	53 (76.9)	546 (11.4)	950 (17.3)
OTC pharmaceuticals		1,321 (9.1)	4,098 (1.3)	5,247 (0.6)	1,301 (1.5)	4,058 (1.0)	5,300 (1.0)

lower : year on year percentage change

*Forecasts in this report are based on the currently available information. Actual results may differ materially depending on a number of factors including adverse economic conditions, etc..